Thus, we hypothesized that the synergy between decrease PTPN13 and increased ErbB2 activation that drives tumor growth and invasion is mediated via EphrinB1 and, further, that EphrinB1-mediated signaling is enhanced in breast cancers with compromised PTPN13 expression. This evidence concerns the gene ERBB2 and neoplasm.